Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of first choice is metformin. However, some people cannot tolerate metformin, which causes diarrhoea in about 10%, and it cannot be used in people with renal impairment. This review appraises three of the newest class of drugs for monothe...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- NIHR Journals Library Publisher's website
- Health Technology Assessment Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- Queen’s Printer and Controller of HMSO
- Copyright date:
- © Queen’s Printer and Controller of HMSO 2017. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.